GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks

GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks

Source: 
Fierce Pharma
snippet: 

With the federal spotlight on e-cigarette use, the FDA has grown increasingly wary of nicotine-based products with risks of abuse. That didn’t stop GlaxoSmithKline from winning a recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy. An FDA panel voted 9-6 to recommend GSK’s oral spray for approval for users 18 and older.